What price ranges did the CSTL share sales cover?

The 2,807-share sale was executed at prices ranging from $35.21 to $36.19, inclusive; the 1,346-share sale ranged from $36.21 to $36.78, inclusive. The reported prices are weighted averages.

Castle Biosciences COO sells 4,153 shares

The reported sale prices are weighted averages of trades ranging from $35.21 to $36.19 and from $36.21 to $36.78, respectively.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Castle Biosciences Inc. Chief Operating Officer Kristen M. Oelschlager exercised fully vested options for 4,153 common shares on October 1, 2026, at a $3.38 exercise price, then sold 2,807 shares at a weighted-average $35.75 and 1,346 shares at a weighted-average $36.38. The transactions were made under a Rule 10b5-1 plan adopted March 17, 2026. Her indirect holdings included 72,649 common shares held by the Fritz Shorter Trust, of which she and her spouse are trustees and beneficiaries; the reported option position following the transaction was 8,305 shares.

Insider Trade Summary 10b5-1

Exercise and Sale: 4,153 shares ($135K approx. pre-tax spread)

Exercise and Sale 5 txns

Insider Oelschlager Kristen M

Role Chief Operating Officer

Sold 4,153 shs ($149K)

Approx. gross sale proceeds $149K

Approx. exercise cost $14K

Approx. pre-tax spread $135K

Type	Security	Shares	Price	Value
Exercise	Stock option (right to buy) ^{F1, F5}	4,153	$0.00	$0.00
Exercise	Common Stock ^F1	4,153	$3.38	$14K
Sale	Common Stock ^{F1, F2}	2,807	$35.75	$100K
Sale	Common Stock ^{F1, F3}	1,346	$36.38	$49K
holding	Common Stock ^F4	--	--	--

Holdings After Transaction: Stock option (right to buy) — 8,305 contracts (Direct); Common Stock — 13,356 shares (Direct); Common Stock — 72,649 shares (Indirect, The Fritz Shorter Trust)

Footnotes (5)

F1. These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, on March 17, 2026.
F2. This transaction was executed in multiple trades at prices ranging from $35.21 to $36.19, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3. This transaction was executed in multiple trades at prices ranging from $36.21 to $36.78, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F4. Held by the Fritz Shorter Trust of which the Reporting Person and her spouse are the trustees and beneficiaries.
F5. The shares subject to the option are fully vested.

Key Figures

Options exercised: 4,153 shares Exercise price: $3.38 per share Shares sold: 2,807 shares +5 more

8 metrics

Options exercised 4,153 shares October 1, 2026

Exercise price $3.38 per share Options exercised October 1, 2026

Shares sold 2,807 shares October 1, 2026; weighted-average sale price $35.75 per share

Weighted-average sale price $35.75 per share Sale of 2,807 shares on October 1, 2026

Shares sold 1,346 shares October 1, 2026; weighted-average sale price $36.38 per share

Weighted-average sale price $36.38 per share Sale of 1,346 shares on October 1, 2026

Option position following transaction 8,305 shares Reported after the October 1, 2026 transaction

Indirect common shares 72,649 shares Held by the Fritz Shorter Trust

Key Terms

Rule 10b5-1 plan, weighted-average sale price, fully vested, Stock option (right to buy)

4 terms

Rule 10b5-1 plan regulatory

"made pursuant to a Rule 10b5-1 plan"

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

weighted-average sale price financial

"price reported above reflects the weighted-average sale price"

fully vested financial

"shares subject to the option are fully vested"

Stock option (right to buy) financial

"Stock option (right to buy)"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many CSTL shares did Kristen M. Oelschlager receive from her option exercise?

Kristen M. Oelschlager exercised options for 4,153 CSTL common shares on October 1, 2026, at a $3.38 exercise price. The options were fully vested, and the transaction was made under a Rule 10b5-1 plan adopted March 17, 2026.

How many CSTL shares did the chief operating officer sell, and at what prices?

She sold 2,807 shares at a weighted-average $35.75 and 1,346 shares at a weighted-average $36.38 on October 1, 2026.

When do the options reported after the CSTL exercise expire?

The reported stock options expire on March 12, 2029.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 10/05/2026 - 04:08 PM Accepted by SEC EDGAR 10/05/2026 - 04:07 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Oelschlager Kristen M

(Last)

(First)

(Middle)

C/O CASTLE BIOSCIENCES, INC.

1500 W. PARKWOOD AVE SUITE 400

(Street)

FRIENDSWOOD

TEXAS

77546

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CASTLE BIOSCIENCES INC [ CSTL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Operating Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	10/01/2026		M⁽¹⁾		4,153	A	$3.38	17,509	D
Common Stock	10/01/2026		S⁽¹⁾		2,807	D	$35.75⁽²⁾	14,702	D
Common Stock	10/01/2026		S⁽¹⁾		1,346	D	$36.38⁽³⁾	13,356	D
Common Stock								72,649	I	The Fritz Shorter Trust⁽⁴⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock option (right to buy)	$3.38	10/01/2026		M⁽¹⁾			4,153	⁽⁵⁾	03/12/2029	Common Stock	4,153	$0	8,305	D

Explanation of Responses:

1. These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person, on March 17, 2026.

2. This transaction was executed in multiple trades at prices ranging from $35.21 to $36.19, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

3. This transaction was executed in multiple trades at prices ranging from $36.21 to $36.78, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

4. Held by the Fritz Shorter Trust of which the Reporting Person and her spouse are the trustees and beneficiaries.

5. The shares subject to the option are fully vested.

Remarks:

	/s/ Frank Stokes, Attorney-in-fact	10/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR